Nektar Therapeutics (NKTR) Misses Q4 EPS by 3c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $57.44 -5.79%
Revenue Growth %: -11.4%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -11.4%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.57), $0.03 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $39.8 million versus the consensus estimate of $45.92 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- AppLovin drops 3% as Edgewater analyst warns of stalled market share growth
- Worthington Industries (WOR) Tops Q1 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
